Search research articles
Contact Us
Filters
Showing results (81-90 of 85) with videos related to
Page
of 9
Sort By:
You have reached the last page of results.
This site can display upto 85 results.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Journal of Hepatology
|
November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Therapeutic Advances in Medical Oncology
|
November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Cancer Immunology, Immunotherapy : CII
|
September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Cancer Immunology, Immunotherapy : CII
|
April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Francesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Page
of 9
Search research articles
Search
Showing results (81-90 of 85) with videos related to
Sort By:
Page
of 9
You have reached the last page of results.
This site can display upto 85 results.
European Urology Oncology
|
July 22, 2023
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni, Sebastiano Buti, Zin W Myint, et al.
Journal of Hepatology
|
November 16, 2023
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours
Ciro Celsa, Giuseppe Cabibbo, Claudia A M Fulgenzi, et al.
Therapeutic Advances in Medical Oncology
|
November 23, 2020
Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors: prospective analysis from a multicentre observational trial by FICOG
Melissa Bersanelli, Diana Giannarelli, Ugo De Giorgi, et al.
Cancer Immunology, Immunotherapy : CII
|
September 7, 2023
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
Ondřej Fiala, Sebastiano Buti, Hideki Takeshita, et al.
Cancer Immunology, Immunotherapy : CII
|
April 18, 2024
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Francesco Massari, Matteo Santoni, Hideki Takeshita, et al.
Page
of 9